North Carolina is currently home to 2646 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
NCT06291324
Recruiting
The purpose of this study is to evaluate the feasibility of using a commercial WATD (Wearable Activity Tracker Device) to collect HRV (Heart Rate Variability) data from pancreatic and breast cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Pancreatic Cancer, Breast Cancer
Register for Updates
A Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia
NCT05934851
Recruiting
The purpose of this study is to compare "Frozen-Section Directed Excision", which has been a proven method of surgery used in dermatology, versus the current, standard method called "Wide Local Excision" to treat high-grade vulvar dysplasia.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Vulvar Neoplasm, Dysplasia Vulvar
Register for Updates
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931
Recruiting
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Atrium Health Levine Cancer Institute, Charlotte, North Carolina
Conditions: Endometrial Cancer
Register for Updates
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663
Recruiting
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this study is to test whether Gemcitabine + Docetaxel is a better or worse treatment than the usual BCG therapy approach. The primary objective of this study is to determine the event free survival (EFS) of BCG-naïve high gr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Non-muscle-invasive Bladder Cancer
Register for Updates
Coconut Oil to Prevent Mouth Sores in Pediatric Patients Receiving High Dose Chemotherapy
NCT05441813
Recruiting
The purpose of this study is to learn if virgin coconut oil (VCO) mouth rinse can help prevent oral mucositis. The Study Investigator will compare standard of care mucositis prevention rinses with the VCO mouth rinse added to the standard of care mucositis prevention rinses. The severity of oral mucositis between the 2 groups will be evaluated. Some of the standard of care rinses that can be used to prevent mucositis are normal saline, Benadryl (diphenhydramine), Mylanta, lidocaine, or other com... Read More
Gender:
ALL
Ages:
Between 7 years and 26 years
Trial Updated:
01/20/2025
Locations: Atrium Health Levine Children's Hospital, Charlotte, North Carolina
Conditions: Oral Mucositis
Register for Updates
Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients
NCT04948619
Recruiting
Pediatric cancer survivors have increased infection-related morbidity and mortality. This study will evaluate immune dysfunction following cancer directed systemic therapy completion, with attention to clinical relevance and infection rate in this population compared to healthy siblings, when applicable. The investigators will also restart vaccinations at earlier time points than previously studied, at 3 months post therapy, and will assess whether boosters or revaccination schedules are superio... Read More
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
01/20/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Pediatric Cancer
Register for Updates
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
NCT04174742
Recruiting
The overall purpose of this study is to investigate whether younger subjects report pain with pegfilgrastim (or biosimilar substitution) more often and/or at higher levels (greater intensity) than older subjects.This study will be carried out throughout the course of your chemotherapy treatment, which will be prescribed by your study doctor. Participation in this study will not affect your cancer treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Breast
Register for Updates
Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy
NCT03555851
Recruiting
This study will examine the influence of donor and recipient pharmacogenetics (PG), drug pharmacokinetics (PK), and T cell phenotypes and how it may permit a tailored dosing strategy to improve the therapeutic index of post-transplant cyclophosphamide (PTCy) and optimize the graft versus tumor effect, while minimizing acute and chronic graft versus host disease (GVHD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Leukemia, Not Otherwise Specified, Leukemia, Other
Register for Updates
First In Human Study of CX-2051 in Advanced Solid Tumors
NCT06265688
Recruiting
The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Carolina BioOncology Institute, PLLC, Huntersville, North Carolina
Conditions: Solid Tumor, Adult
Register for Updates
Cord Clamping Among Neonates with Congenital Heart Disease
NCT06153459
Recruiting
The goal of this clinical trial is to compare 2 different timepoints for clamping the umbilical cord at birth for term-born infants with a prenatal diagnosis of congenital heart disease (CHD). The main questions it aims to answer are: * Does Delayed Cord Clamping at 120 seconds (DCC-120) or Delayed Cord Clamping at 30 seconds (DCC-30) after birth lead to better health outcomes? * Does DCC-120 seconds or DCC-30 seconds after birth lead to better neuromotor outcomes at 22-26 months of infant age... Read More
Gender:
ALL
Ages:
Between 37 weeks and 42 weeks
Trial Updated:
01/17/2025
Locations: Duke Children's Hospital & Health Center, Durham, North Carolina
Conditions: Congenital Heart Disease (CHD)
Register for Updates
RCT of Sensor-controlled Digital Game for Hypertension Self-care in a Native American Community
NCT05671406
Recruiting
This study evaluates a sensor-controlled digital game (SCDG) to motivate self-management behaviors of physical activity in Native American adults with hypertension (HTN). Half of the participants will receive the SCDG app and physical activity sensors and the other half will receive only the physical activity sensors. Native American participants with hypertension (HTN) in the sensor controlled digital game intervention group will show increased PA behaviors; improved HTN knowledge, self-care b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: University of North Carolina Chapel Hill, Chapel Hill, North Carolina
Conditions: Hypertension
Register for Updates
Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma
NCT05376592
Recruiting
A major complication of pancreatic adenocarcinoma (PDAC) is cancer cachexia (CC) which is a complex syndrome characterized by skeletal muscle mass loss (with or without loss of fat mass) and progressive functional impairment not reversible by conventional nutritional support. It is estimated to occur in over 75% of patients with advanced PDAC, the highest incidence of all solid tumors, and contributes significantly to poor outcomes and mortality. Though there is overlap amongst the pathophysiolo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Pancreas Adenocarcinoma, Cachexia
Register for Updates